X0609 4 2026-09-01 0001604821 Natera, Inc. NTRA 0002010019 Moshkevich Solomon false C/O NATERA, INC. 13011 MCCALLEN PASS BUILDING A SUITE 100 AUSTIN TX 78753 false true false false PRESIDENT, CLINICALDIAGNOSTICS 1 Common Stock 2026-09-01 4 S 0 1000 319.7582 D 128019 D Common Stock 2026-09-01 4 S 0 1400 320.9225 D 126619 D Common Stock 2026-09-01 4 S 0 600 321.9067 D 126019 D Common Stock 2026-09-02 4 S 0 15160 326.8940 D 110859 D The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.2850 to $320.26 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $320.36 to $321.17 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $321.49 to $322.11 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on August 25, 2023. /s/ Tami Chen, Attorney-in-Fact 2026-09-03